Fate Therapeutics Company Profile (NASDAQ:FATE)

About Fate Therapeutics

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FATE
  • CUSIP:
Key Metrics:
  • Previous Close: $4.02
  • 50 Day Moving Average: $3.10
  • 200 Day Moving Average: $2.82
  • 52-Week Range: $34,148,000.00 - $1.47
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.24
  • P/E Growth: 0.00
  • Market Cap: $138.98M
  • Outstanding Shares: 34,148,000
  • Beta: 1.2
Profitability:
  • Net Margins: -740.69%
  • Return on Equity: -112.48%
  • Return on Assets: -58.58%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 3.23%
  • Quick Ratio: 3.23%
Additional Links:
Companies Related to Fate Therapeutics:

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.40 (57.25% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetDetails
12/6/2016BMO Capital MarketsReiterated RatingOutperform$4.00View Rating Details
11/8/2016WedbushLower Price TargetOutperform$8.00 -> $7.00View Rating Details
9/22/2016Roth CapitalInitiated CoverageBuy$8.00View Rating Details
8/9/2016HC WainwrightReiterated RatingBuyView Rating Details
6/21/2016Leerink SwannReiterated RatingOutperform$4.00View Rating Details
5/10/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
11/5/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
10/6/2015Raymond James Financial, Inc.Initiated CoverageOutperform$8.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
11/7/2016Q316($0.29)($0.27)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)ViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$1.10 millionViewN/AView Earnings Details
11/3/2015Q315($0.30)($0.24)$1.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)ViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.37)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.33)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.31)($0.27)($0.29)
Q2 20162($0.35)($0.33)($0.34)
Q3 20164($0.35)($0.29)($0.32)
Q4 20164($0.36)($0.27)($0.33)
Q1 20172($0.24)($0.22)($0.23)
Q2 20172($0.24)($0.23)($0.24)
Q3 20172($0.25)($0.24)($0.25)
Q4 20172($0.26)($0.19)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Insider Ownership Percentage: 13.66%
Institutional Ownership Percentage: 47.08%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.38View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
DateHeadline
fool.com logoBetter Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation (NASDAQ:FATE)
www.fool.com - February 22 at 5:23 PM
News IconFate Therapeutics Inc (NASDAQ:FATE): Our members Picked Up At $3.65, Made An Easy 30% Quickly (NASDAQ:FATE)
www.marketnewscall.com - February 22 at 9:30 AM
News IconWall Street Consensus Watch on Fate Therapeutics, Inc. (NASDAQ:FATE) - Rockville Register (NASDAQ:FATE)
rockvilleregister.com - February 19 at 10:49 AM
News IconStock Perspective: Fate Therapeutics, Inc. (NASDAQ:FATE) Company Earnings Watch - Aiken Advocate (NASDAQ:FATE)
aikenadvocate.com - February 18 at 4:48 PM
openpr.com logoBone Degeneration Therapeutics Market, Company Analysis and Forecast to 2024 (NASDAQ:FATE)
www.openpr.com - February 18 at 10:37 AM
News IconFate Therapeutics, Inc. (NASDAQ:FATE) Experiencing Unusual Activity Mid-day - Winfield Review (NASDAQ:FATE)
winfieldreview.com - February 17 at 3:42 PM
News IconFate Therapeutics, Inc. (NASDA:FATE) A Keeper? – Stock News Union - StockNewsUnion (NASDAQ:FATE)
stocknewsunion.com - February 17 at 3:42 PM
News IconABR Of Fate Therapeutics, Inc. (NASDAQ:FATE) Stock At 1.17 - Stock Observer (NASDAQ:FATE)
www.thestockobserver.com - February 17 at 9:18 AM
News IconInside the Numbers: Looking at This Stock: Fate Therapeutics Inc. (FATE) - BVN (NASDAQ:FATE)
bvnewsjournal.com - February 17 at 9:18 AM
News IconBone Degeneration Therapeutics Market Research Report Forecast to 2024 (NASDAQ:FATE)
www.pressbox.co.uk - February 16 at 10:08 PM
nasdaq.com logoForget Gilead, Buy These 5 Biotech Stocks Instead - Nasdaq - Nasdaq (NASDAQ:FATE)
www.nasdaq.com - February 13 at 5:58 PM
openpr.com logoBone Degeneration Therapeutics Market: New Business Opportunities & Investment Research Report 2024 (NASDAQ:FATE)
www.openpr.com - February 10 at 3:50 AM
News IconFate Therapeutics, Inc. (NASDAQ:FATE) Projected EPS At $-0.29 - Stock Observer (NASDAQ:FATE)
www.thestockobserver.com - February 8 at 5:38 PM
News IconFate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference - EconoTimes (NASDAQ:FATE)
www.econotimes.com - February 8 at 5:38 PM
finance.yahoo.com logoFate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:FATE)
finance.yahoo.com - February 8 at 5:38 PM
openpr.com logoBone Degeneration Therapeutics Market - Trends, Outlook, and Opportunity Analysis, 2024 (NASDAQ:FATE)
www.openpr.com - February 7 at 6:21 PM
News IconBone Degeneration Therapeutics Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 (NASDAQ:FATE)
www.medgadget.com - February 4 at 10:16 PM
investornewswire.com logoSentiments And Ratings Alert: Fate Therapeutics, Inc. (NASDAQ:FATE) - Investor Newswire (NASDAQ:FATE)
www.investornewswire.com - February 4 at 5:16 PM
News IconInvesting Focus: Indicators in View on Shares of Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - February 2 at 5:39 PM
News IconChecking Indicator Levels for Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - February 1 at 10:43 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Fate Therapeutics, Inc. (NASDAQ:FATE) - Nelson Research (NASDAQ:FATE)
nelsonobserver.com - February 1 at 10:43 PM
News IconInvestor Notebook: Taking a Look at Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - The Tribune (NASDAQ:FATE)
lakecitytribune.com - January 31 at 10:50 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Fate Therapeutics, Inc. (NASDAQ:FATE) - Nelson Research (NASDAQ:FATE)
nelsonobserver.com - January 31 at 10:50 PM
News IconPlacing This Stock in the Hotbed: Fate Therapeutics, Inc. (NASDAQ:FATE) - Prospect Journal (NASDAQ:FATE)
prospectjournal.com - January 31 at 10:50 PM
News IconAre Insiders Bumping Up Their Positions in Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 31 at 10:50 PM
openpr.com logoBone Degeneration Therapeutics Market 2016 - 2024; Emerging niche segments and regional markets (NASDAQ:FATE)
www.openpr.com - January 31 at 5:50 PM
openpr.com logoBone Degeneration Therapeutics Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 (NASDAQ:FATE)
www.openpr.com - January 30 at 5:50 PM
News IconTraders are Taking a Closer Look at These Shares: Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - January 30 at 12:10 PM
News IconIgniting Curiosity on This Name, Investor Update on Fate Therapeutics, Inc. (NASDAQ:FATE) - Prospect Journal (NASDAQ:FATE)
prospectjournal.com - January 30 at 12:10 PM
News IconWith increased physical inactivity, Bone Degeneration Therapeutics Market witness handsome growth in upcoming years (NASDAQ:FATE)
www.medgadget.com - January 27 at 6:52 PM
News IconAegis Reiterates Buy Rating for Ocera Therapeutics Inc. (OCRX) (NASDAQ:FATE)
prensariotiretail.com - January 26 at 11:37 PM
News IconTechnical Action Update on Shares of Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - January 26 at 6:34 PM
News IconInvestor Watch: Volatility Review for Fate Therapeutics, Inc. (NASDAQ:FATE) - The Tribune (NASDAQ:FATE)
lakecitytribune.com - January 26 at 6:34 PM
sbwire.com logoBone Degeneration Therapeutics Market 2016 - 2024; Driven by Rising Obesity and Increasing Rate of Diabetes Across the Globe (NASDAQ:FATE)
www.sbwire.com - January 25 at 11:30 PM
reuters.com logoBRIEF-Fate Therapeutics files to say resale of up to 20.9 mln shares of common (NASDAQ:FATE)
www.reuters.com - January 25 at 11:30 PM
News IconMonitoring Relative Strength Index Values for Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - January 25 at 6:29 PM
News IconEarnings in Full Force, Analysts Take Aim at Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 25 at 6:29 PM
News IconAre Insiders Filling Their Own Pockets With Shares? Insider Update on Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 24 at 3:31 AM
News IconFate Therapeutics, Inc. (NASDAQ:FATE) Projected EPS At $-0.29 ... - Stock Observer (NASDAQ:FATE)
www.thestockobserver.com - January 24 at 3:31 AM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 24 at 3:31 AM
News IconPriming The Pump: Stock Volatility Spotted in Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 24 at 3:31 AM
News IconTraders are Keeping Track of Technicals on Shares of Fate Therapeutics Inc. (FATE) - Sherwood Daily (NASDAQ:FATE)
sherwooddaily.com - January 22 at 10:02 PM
News IconOnconova Therapeutics Inc. (ONTX) Receives Average Rating of "Strong Buy" from Analysts (NASDAQ:FATE)
prensariotiretail.com - January 22 at 5:00 PM
News IconThis Weeks Target Prices For Cidara Therapeutics, Inc. (CDTX) (NASDAQ:FATE)
larampadinapoli.com - January 22 at 5:00 PM
News IconTechnical Trading: Focus on Shares of Fate Therapeutics Inc. (FATE) - Rives Journal (NASDAQ:FATE)
rivesjournal.com - January 20 at 11:27 PM
News IconStock Update on Earnings & Estimates for Fate Therapeutics, Inc ... - Aiken Advocate (NASDAQ:FATE)
aikenadvocate.com - January 20 at 11:27 PM
News IconAmplified Volatility Spotted in Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 20 at 11:27 PM
zacks.com logoFate Therapeutics (FATE) Shares March Higher, Can It Continue? (NASDAQ:FATE)
www.zacks.com - January 20 at 4:50 AM
News IconCutting the Mustard Mid-Session: Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 18 at 10:35 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Fate Therapeutics, Inc. (NASDAQ:FATE) - Wall Street Beacon (NASDAQ:FATE)
wsbeacon.com - January 18 at 10:35 PM

Social

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?

6 equities research analysts have issued 12-month price targets for Fate Therapeutics' shares. Their predictions range from $4.00 to $9.00. On average, they expect Fate Therapeutics' share price to reach $6.40 in the next year.

When will Fate Therapeutics announce their earnings?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Fate Therapeutics stock?

Fate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (17.80%), FMR LLC (12.86%), Kingdon Capital Management L.L.C. (7.66%) and Renaissance Technologies LLC (0.61%). Company insiders that own Fate Therapeutics stock include Chris Storgard and William H Rastetter.

Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C..

Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?

Fate Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC and Renaissance Technologies LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter.

How do I buy Fate Therapeutics stock?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Fate Therapeutics stock cost?

One share of Fate Therapeutics stock can currently be purchased for approximately $4.07.

Fate Therapeutics (NASDAQ:FATE) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Earnings History Chart

Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)

Dividend History Chart

Dividend Payments by Quarter for Fate Therapeutics (NASDAQ:FATE)

Last Updated on 2/26/2017 by MarketBeat.com Staff